66845-32-7

Basic information

• Product Name: Nsc290127
• Synonyms: Nsc290127;Oxaliplatin Related Compound F (25 mg) ([SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N') diiodidoplatinum(II));Oxaliplatin Related CoMpound F;(trans-R,R-1,2-Diaminocyclohexane)diiodoplatinum;Diiodo(trans-l-1,2-cyclohexanediamine)platinum
• CAS NO: 66845-32-7
• Molecular Formula: C6H14I2N2Pt
• Molecular Weight: 563.0757
• Mol File: 66845-32-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 193.6°C at 760 mmHg
• Flash Point: 75°C
• Appearance: /
• Vapor Pressure: 0.46mmHg at 25°C
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly)
• CAS DataBase Reference: Nsc290127(CAS DataBase Reference)
• NIST Chemistry Reference: Nsc290127(66845-32-7)
• EPA Substance Registry System: Nsc290127(66845-32-7)

Safety Data

• Hazardous Substances Data: 66845-32-7(Hazardous Substances Data)

Usage

Uses

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-κN,κN'')diiodoplatinum is a potential antitumor agent. Impurity of Oxiplatin (O845075), third generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic.

InChI:InChI=1/C6H12N2.2HI.Pt/c7-5-3-1-2-4-6(5)8;;;/h5-8H,1-4H2;2*1H;/q-2;;;+4/p-2/rC6H12N2.I2Pt/c7-5-3-1-2-4-6(5)8;1-3-2/h5-8H,1-4H2;/q-2;+2

Upstream product

• 694-83-7 rac-diaminocyclohexane 
• 7681-11-0 potassium iodide 
• 10025-99-7 potassium tetrachloroplatinate(II) 
• 1121-22-8 trans-1,2-Diaminocyclohexane 

Downstream Products

• 66900-71-8 (dach)Pt(SO₄) 
• 38780-40-4 {(1R,2R)-cyclohexane-1,2-diamine}dichloridoplatinum(II) 
• 61848-66-6 cis-dichloro-(cis-1,2-diaminocyclohexane)platinum(II) 
• 1428416-33-4 [2-(2-diethylaminoethyl)succinato][cis-(1,2-trans-cyclohexanediamine)]platinum(II) tosylate 

Relevant articles and documents

In vitro and in vivoactivity of series of cationic dinuclearPt(II) complexes

The antitumour potential of nine dinuclear platinum(II) complexes of the type [{Pt(L)Cl}2(μ-X)]2+(where L represents two NH3 or different bidentantly coordinated diamine ligand - ethylenediamine, en; (±)-1,2-propylenediamine, 1,2-pn; isobutylenediamine, ibn; trans-(±)-1,2-diaminocyclohexane, dach; 1,3-propylenediamine, 1,3-pd; 2,2-dimethyl-1,3-propylenediamine, 2,2-diMe-1,3-pd; (±)-1,3-pentanediamine,1,3-pnd, and X is a bridging pyrazine (pz) or pyridazine (pydz) ligand) were determined by in vitro and in vivo assays using the CT26 cell line and a murine model of heterotopic colon cancer tumour induced in immunocompetent BALB/c mice. This study concludes that complexes Pt1, Pt2 and Pt7 possess significant in vitro cytotoxic activity against mouse colon carcinoma CT26 cells, while all these complexes show moderate apoptotic effect. Complexes Pt1 and Pt7 arrested CT26 cells in G2/M phase of cell cycle, while, evaluated by detection of Ki67 expressing cells, complexes Pt5 and Pt6 exerted the highest antiproliferative effect. Complexes Pt1 and Pt2 exerted significant in vivo antitumour effects. These complexes reduced the growth of primary tumour and the incidence of lung and liver metastases without causing the significant hepato- and nephro- toxicity. Our data indicate considerable antitumour activity of platinum(II) complexes against CT26 cells in vitro and in vivo and imply possible further investigations on their role as potential chemotherapeutic agents.

A method for the treatment of tumor cell proliferative diseases of platinum (II) compound

Disclosed are a platinum compound with the leaving group malonic derivative "2" position substituent containing a primary amino, a secondary amino, a tertiary amino, and a quaternary amino, as well as pharmaceutically acceptable salt, preparation method thereof, and pharmaceutical composition containing the compound. Also disclosed are uses of the compound for treating cell proliferative diseases, particularly cancers. The platinum compound of the present invention has the high water solubility and the low toxicity.

PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO

Disclosed are a class of platinum compounds of malonic acid derivatives having a leaving group containing an amino or alkylamino, and pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition containing the compou